PDF herunterladen
Semin Thromb Hemost 2001; 27(5): 523-530
DOI: 10.1055/s-2001-17962
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Development of Direct Thrombin Inhibitors in Comparison with Glycosaminoglycans

Fritz Markwardt
  • 1Professor of Pharmacology, International Institute of Thrombosis, Vascular Diseases, Erfurt-Frienstedt, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. Oktober 2001 (online)

    Lizenzen und Reprints

ABSTRACT

The progress in molecular biology has stimulated interest in the structure and function of thrombin. It has improved the understanding of its central role in thrombogenesis and has clarified the molecular events of inhibitor binding. This development has resulted in the production of recombinant hirudins and the design of hirudin analogues. It has also allowed the molecular design of synthetic antithrombins and encouraged the development of these products for clinical use. All pharmacological aspects speak in favor of the use of the direct thrombin inhibitors as antithrombotic agents, especially in the potential indications in which thrombin plays a crucial role in the pathogenesis. If their apparent advantages in comparison to glycosaminoglycans can be shown effectively, the direct thrombin inhibitors may become the drug of choice for certain indications.

KEYWORD

Thrombin inhibitors - glycosaminoglycans - hirudin - heparin - effects - clinical use

REFERENCES

  • 1 Markwardt F. Blutgerinnungshemmende Wirkstoffe aus blutsaugenden Tieren.  Jena: Gustav Fischer; 1963
    Suche in Google Scholar
  • 2 Markwardt F, Landmann H. Blutgerinnungshemmende Proteine, Peptide und Aminosäurederivate. In: Markwardt F, ed. Handbuch der experimentellen Pharmakologie, Bd 27: Anticoagulantien. New York: Springer 1971: 76-142
    Suche in Google Scholar
  • 3 Markwardt F. Coagulation inhibitors of blood-sucking animals-A new line of developing antithrombotic drugs.  Pharmazie . 1993;  49 313-316
    PubMedSuche in Google Scholar
  • 4 Markwardt F. Antithrombotic agents from hematophagous animals.  Clin Appl Thromb Hemost . 1996;  2 75-82
    PubMedSuche in Google Scholar
  • 5 Markwardt F. Isolierung und chemische Charakterisierung des Hirudins.  Hoppe Seylers Z Physiol Chem . 1957;  308 147-156
    PubMedSuche in Google Scholar
  • 6 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombin-Inhibitors Hirudin.  Hoppe Seylers Z Physiol Chem . 1967;  348 1381-1386
    PubMedSuche in Google Scholar
  • 7 Markwardt F. Hirudin as an inhibitor of thrombin. In: Colowick SP, Kaplan NO, eds. Methods in Enzymology Vol. XIX, Proteolytic Enzymes. New York: Academic Press 1970: 924-932
    Suche in Google Scholar
  • 8 Markwardt F. Development of hirudin as an antithrombotic agent.  Semin Thromb Hemost . 1989;  15 269-282
    PubMedSuche in Google Scholar
  • 9 Markwardt F. Hirudin and derivatives as anticoagulant agents.  Thromb Haemost . 1991;  66 141-152
    PubMedSuche in Google Scholar
  • 10 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent.  Biomed Biochim Acta . 1985;  44 1007-1013
    PubMedSuche in Google Scholar
  • 11 Markwardt F. Le genie genetique conduit au retour de l'hirudine comme anticoagulant.  Sang Thromb Vaisseaux . 1991;  3 519-522
    PubMedSuche in Google Scholar
  • 12 Markwardt F. The development of hirudin as an antithrombotic drug. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley and Belfus 1997: 145-160
    Suche in Google Scholar
  • 13 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.  Thromb Haemost . 1982;  47 226-229
    PubMedSuche in Google Scholar
  • 14 Markwardt F, Fink E, Kaiser B. Pharmacological survey of recombinant hirudin.  Pharmazie . 1988;  43 202-207
    PubMedSuche in Google Scholar
  • 15 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin.  Thromb Res . 1989;  54 377-388
    CrossrefPubMedSuche in Google Scholar
  • 16 Markwardt F. Synthetic, low molecular weight thrombin inhibitors. A new concept of anticoagulants?.  Haemostasis . 1974;  3 185-202
    PubMedSuche in Google Scholar
  • 17 Markwardt F. Pharmacological control of blood coagulation by synthetic, low-molecular-weight inhibitors of clotting enzymes. A new concept of anticoagulants.  Trends Pharmacol Sci . 1980;  1 153-157
    CrossrefPubMedSuche in Google Scholar
  • 18 Markwardt F. Pharmacologic control of blood coagulation by synthetic, low molecular weight inhibitors of clotting enzymes.  Ann NY Acad Sci . 1981;  370 757-764
    PubMedSuche in Google Scholar
  • 19 Markwardt F. Development of synthetic proteinase inhibitors as anticoagulant agents. In: Harenberg D, Heene L, Stehle G, Schettler G, eds. New Trends in Haemostasis, Coagulation Proteins, Endothelium and Tissue Factors NewYork: Springer 1990: 177-187
    Suche in Google Scholar
  • 20 Hauptmann J, Markwardt F. Pharmacological aspects of the development of selective synthetic thrombin inhibitors as anticoagulants.  Semin Thromb Hemost . 1992;  18 200-217
    PubMedSuche in Google Scholar
  • 21 Markwardt F, Klöcking H P. Antithrombotic effect of synthetic thrombin inhibitors.  Thromb Res . 1972;  1 243-252
    CrossrefPubMedSuche in Google Scholar
  • 22 Markwardt F, Nowak G, Stürzebecher J, Griessbach U, Walsmann P. Clinico-pharmacological studies with recombinant hirudin.  Thromb Res . 1988;  52 393-400
    CrossrefPubMedSuche in Google Scholar
  • 23 Markwardt F, Nowak G, Stürzebecher J. Clinical pharmacology of recombinant hirudin.  Haemostasis . 1991;  21 133-136
    PubMedSuche in Google Scholar
  • 24 Eschenfelder V. Pharmacologic considerations in the development of hirudin and its derivatives for cardiovascular indications. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley and Belfus Inc. 1997: 161-174
    Suche in Google Scholar
  • 25 Richter M, Walsmann P, Markwardt F. Plasma level of dextran-r-hirudin.  Pharmazie . 1989;  44 73-74
    PubMedSuche in Google Scholar
  • 26 Markwardt F, Richter M, Walsmann P, Riesener G, Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behavior.  Biomed Biochim Acta . 1990;  49 1103-1126
    PubMedSuche in Google Scholar
  • 27 Hauptmann J, Kaiser B, Markwardt F. Anticoagulant action of synthetic tight binding inhibitors of thrombin in vitro and in vivo.  Thromb Res . 1985;  39 711-715
    CrossrefPubMedSuche in Google Scholar
  • 28 Hauptmann J, Stürzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside.  Thromb Res . 1999;  93 203-241
    CrossrefPubMedSuche in Google Scholar
  • 29 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors.  Thromb Res . 1986;  43 613-620
    CrossrefPubMedSuche in Google Scholar
  • 30 Hauptmann J, Brüggener E, Markwardt F. Effect of heparin, hirudin and a synthetic thrombin inhibitor on antithrombin III in thrombin induced disseminated intravascular coagulation in rats.  Haemostasis . 1987;  17 321-328
    PubMedSuche in Google Scholar
  • 31 Markwardt F. Hirudin: the promising antithrombotic.  Cardiovasc Drug Rev . 1992;  10 211-232
    PubMedSuche in Google Scholar
  • 32 Erikson B I, Wille-Jørgenson P, Kälebo P. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
    CrossrefPubMedSuche in Google Scholar
  • 33 Markwardt F. Pharmacology of selective thrombin inhibitors.  Nouv Rev Fr Hematol . 1988;  30 161-165
    PubMedSuche in Google Scholar